Note: Ingredients listed on restricted chemical lists
EC/CAS
77-92-9
Name of the chemical
Citric acid
Concentration
N/A
EC/CAS
99-76-3
Name of the chemical
4-hydroxybenzoic acid, methyl ester
Concentration
N/A
EC/CAS
94-13-3
Name of the chemical
Propylparaben; propyl 4-hydroxybenzoate
Concentration
N/A
General Information
Version
00
Revision date
2015-03-10
Product name
Trihexyphenidyl Hydrochloride Oral Solution, USP
Product Synonyms
Compare to Artane®
1.2.1 Relevant identified uses
Pharmaceutical product used as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic)
Emergency telephone
800.424.9300
Icons in SDS
Company Information
company name
Pharmaceutical Associates, Inc
Section 2
SECTION 2: Hazards identification
OSHA Hazards Classification This product is a mixture and is a pharmaceutical product. It is considered non-
Precautionary statements
General advice: Seek medical attention in case of accidental exposure or overdose. Eyes: Avoid contact with eyes. Skin Contact: Avoid skin contact. Inhalation: Not intended for inhalation. Ingestion: Generally safe at recommended doses. In case of overdose, seek medical attention immediately.
Storage
There are no special storage conditions for safety. For product integrity, store under conditions specified on the label.
Disposal
Dispose of in accordance with applicable laws and regulations.
2.1 Classification of the substance or mixture
This product is a mixture and is a pharmaceutical product. It is considered non- Hazardous according to the OSHA Hazard Communication Standard 2012 (29 CFR 1910.1200). Chemical family: Mixture Statement of Hazard: May be harmful if swallowed. May cause central nervous system effects. Additional Hazard Information: Short term: Potential side effects associated with the use of any atropine-like drugs, including trihexyphenidyl, include cognitive dysfunctions, including confusion and memory impairment; constipation, drowsiness, urinary hesitancy or retention, tachycardia, dilation of the pupil, increased intraocular pressure, choreiform movements, weakness, vomiting, and headache. Exacerbation of parkinsonism with abrupt treatment withdrawal has been reported. Neuroleptic malignant syndrome with abrupt treatment withdrawal has been reported. Long term: Not Available EU Indication of danger: Not classified. Emergency overview Seek medical attention in case of accidental exposure or overdose. The product is generally safe when used as prescribed. Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential of exposure in your workplace. 00
